Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA FE 1 20 versus BALZIVA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA FE 1 20 versus BALZIVA 28.
AUROVELA FE 1/20 vs BALZIVA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. Inhibits ovulation by suppressing gonadotropin release (FSH, LH). Increases viscosity of cervical mucus, reducing sperm penetration. Alters endometrial lining to reduce implantation likelihood.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by one iron tablet (75 mg ferrous fumarate) orally once daily for 7 days.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours (with interindividual variability).
2.5 hours; clinically relevant for dosing interval in renal impairment
Renal: ~50-60% as metabolites; fecal: ~40-50% as metabolites; biliary excretion contributes to fecal elimination.
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Category C
Category C
Oral Contraceptive
Oral Contraceptive